Type 2 diabetes (T2D) and heart health have a complex and dependent relationship. New data presented at ACC 2026 suggests that dulaglutide may be doing something far more dramatic than managing ...

For older adults with type 2 diabetes, the risk for dementia seems similar with sodium-glucose cotransporter 2 (SGLT2) inhibitors and the glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

The FDA has approved Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for CV events.

Please provide your email address to receive an email when new articles are posted on . Adults with type 2 diabetes using tirzepatide had a 20% lower risk for major adverse CV events than those using ...

An analysis of patient-reported outcomes (PROs) from the SURPASS-SWITCH trial found that adults with type 2 diabetes who switched from dulaglutide to tirzepatide not only saw stronger improvements in ...

Dulaglutide injection should be given subcutaneously in the abdomen, thigh or upper arm once e every week at any time of the day. The initial dose is 0.75 mg once a week. The dose can be increased to ...

Dulaglutide reduces liver fat content in patients with type 2 diabetes (T2D) and nonalcoholic fatty liver disease, when used in combination with standard T2D treatment. Although previous data show ...

INDIANAPOLIS, June 9, 2019 /PRNewswire/ -- Detailed results from REWIND, the Trulicity ® (dulaglutide) cardiovascular outcome trial, showed a significant 12 percent reduction in major cardiovascular ...